evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

550 questions · 606 findings · 25 reviews · Oral medicine and oral cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 62 · 10.2%GRADE not reported 428 · 70.6%Very low 69 · 11.4%Low 30 · 5%Moderate 16 · 2.6%High 1 · 0.2%

Polaprezinc vs Azulene oral rinse

Oral pain · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Polaprezinc led to lower oral pain (severe, > 2 on 0-3 scale) compared with azulene oral rinse; GRADE not reported.

1 finding from 1 review

Polaprezinc vs Azulene oral rinse

Disability of oral intake · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Polaprezinc showed no clear difference in disability of oral intake compared with azulene oral rinse; GRADE not reported.

1 finding from 1 review

Oral prednisone plus curcuminoids (adjunctive) vs Oral prednisone plus placebo

Reduction in pain · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review

Integrated Chinese and Western medicine (incl. oral prednisone) vs Western medicine (incl. oral prednisone)

Clinical score · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs placebo

Time to resolution of first ulcer (days) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower time to resolution of first ulcer (days) compared with placebo; GRADE not reported.

1 finding from 1 review

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist)

Time to resolution of first ulcer (days) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower time to resolution of first ulcer (days) compared with montelukast (leukotriene receptor antagonist); GRADE not reported.

1 finding from 1 review

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs placebo

Total number of new lesions over 2-month treatment period · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower total number of new lesions over 2-month treatment period compared with placebo; GRADE not reported.

1 finding from 1 review

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs placebo

Days to resolution of pain / epithelialization; number of aphthae per month · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
  • Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
    2 months
    Femiano 2003 (high risk of bias) reports days to resolution of pain and days to epithelialization of aphthae at 1 month, and number of aphthae per month after the first and second months; data presented as…
    1 study · 20 participants
    GRADE not reported

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs placebo

Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist)

Total number of new lesions over 2-month treatment period · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… showed no clear difference in total number of new lesions over 2-month treatment period compared with montelukast (leukotriene receptor antagonist); GRADE not reported.

1 finding from 1 review

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist)

Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review

Removal of predisposing habits (e.g. tobacco/alcohol cessation) vs Placebo or no treatment

Outcome not reported · People with a diagnosis of oral leukoplakia

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic valaciclovir (lower dose) vs Prophylactic valaciclovir (higher dose)

Presence/absence of HSV oral lesions · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)

Prophylactic valaciclovir (lower dose) showed no clear difference in presence/absence of HSV oral lesions compared with prophylactic valaciclovir (higher dose); GRADE not reported.

1 finding from 1 review

Antifungal drugs not absorbed from GI tract vs placebo or no treatment

Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy

Antifungal drugs not absorbed from GI tract showed no clear difference in oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.

1 finding from 1 review